首页> 外文期刊>Medical science monitor : >Children with acute lymphoblastic leukemia: is there any subgroup of children without elevated thrombin generation? A preliminary study utilizing measurements of thrombin-antithrombin III complexes
【24h】

Children with acute lymphoblastic leukemia: is there any subgroup of children without elevated thrombin generation? A preliminary study utilizing measurements of thrombin-antithrombin III complexes

机译:小儿急性淋巴细胞性白血病:是否有没有亚组的凝血酶升高的儿童?利用凝血酶-抗凝血酶III复合物的测定进行的初步研究

获取原文
           

摘要

The mechanisms contributing to thromboembolic complications in children with acute lymphoblastic leukemia (ALL) are complex, but it is believed that two factors are of critical importance, i.e. increased thrombin generation and decreased antithrombotic potential of the blood plasma. We evaluated generation of thrombin in three periods of observation of the children: a) prior to chemotherapy, b) after remission-inducing chemotherapy, and c) after infusion of L-asparaginase in the consolidation phase. The study group consisted of 23 children (x = 6.8 years of age), and a control group of 11 children (x = 7.3 years of age). Thrombin-antithrombin III complex (TAT) was selected as a marker of thrombin generation and it was measured by ELISA method. TAT levels prior to chemotherapy were found to be normal in a small subgroup of children (7/23 - ca 30%), i.e. they were within the control range (1.5-4.5 μg/l), but all the levels increased following remission-inducing chemotherapy. In contrast, in the major subgroup of children whose TAT levels were elevated at presentation (16/23 - ca 70%) no significant changes were observed following chemotherapy. Conclusion: There is a subgroup of children with ALL whose thrombin generation is normal as measured by its marker - thrombinantithrombin III (TAT). Only in those children thrombin generation increases following chemotherapy.
机译:导致急性淋巴细胞性白血病(ALL)儿童血栓栓塞并发症的机制很复杂,但据信有两个至关重要的因素,即增加的凝血酶生成量和降低的血浆抗血栓形成潜力。我们在观察儿童的三个阶段中评估了凝血酶的产生:a)化疗前,b)诱导缓解的化疗后,c)在巩固期输注L-天冬酰胺酶后。研究组由23名儿童(x = 6.8岁)和对照组的11名儿童(x = 7.3岁)组成。选择凝血酶-抗凝血酶III复合物(TAT)作为凝血酶生成的标志物,并通过ELISA法测定。发现一小部分儿童化疗前的TAT水平正常(7/23-约30%),即处于控制范围内(1.5-4.5μg/ l),但缓解后所有水平均升高-诱导化疗。相反,在主要儿童亚组中,其TAT水平在就诊时升高(16/23-约70%),化疗后未观察到显着变化。结论:有一个亚型的ALL儿童,其标志物-凝血酶抗凝血酶III(TAT)测得凝血酶生成正常。仅在这些儿童中,化疗后凝血酶的产生增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号